Rgenta’s RGT-61159 cleared by FDA for first-in-human trial in adenoid cystic carcinoma and colorectal cancer

July 11, 2024

Rgenta Therapeutics Inc. has received IND clearance by the FDA for RGT-61159, which is being developed for adenoid cystic carcinoma, colorectal cancer and other solid tumors, as well as acute myeloid leukemia.

BioWorld Science Regulatory Cancer FDA IND

Today's news in brief

BioWorld

BioWorld briefs for July 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for July 18, 2025.

Blenrep misstep? ODAC cites tox, GSK dosing neglect in MM

BioWorld

The rough ride presaged by briefing documents came to pass for GSK plc with the drug first approved by the U.S. FDA as Blenrep (belantamab mafodotin, bel-maf), as...

Adcom agrees with FDA: Otsuka’s PTSD treatment needs more study

BioWorld

In a 10-1 vote, the U.S. FDA’s Psychopharmacologic Drugs Advisory Committee said Otsuka Pharmaceutical Co. Ltd.’s studies of its combination post-traumatic stress...

Atai Therapeutics discovers new 5-HT2A receptor partial agonists

BioWorld Science

Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...